# BioCryst Pharmaceuticals Inc. (BCRX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $9.96, market value $2.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). BioCryst Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.03**. A PEG of 0.03 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.7×**. Each dollar of revenue is priced at 2.7×.
- **Free-cash-flow yield: 14.7%** (5-yr avg -1.0%). Free cash flow equals 14.7% of the market value, above its five-year average of -1.0%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.

## Profitability
- **Operating margin: -33.3%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: 30.2%**. 30.2% of each dollar of sales reaches the bottom line.
- **Return on equity: -221.4%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 118.4%**. Return on all capital, debt included, is 118.4%: comfortably above what that capital costs.
- **Return on assets: -74.8%**. Each dollar of assets produces -74.8% of profit.

## Growth
- **Revenue growth (1 yr): 94.1%** (3-yr 47.8%/yr, 5-yr 117.9%/yr). Revenue grew 94.1% over the last year, against 117.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 381.4%**. Earnings per share rose 381.4%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Altman Z-score: 5.98**. A Z-score of 5.98 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. BioCryst Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover BioCryst Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $20.82 (+109% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 20.4%** (YTD 27.7%, 3-mo 18.4%). The shares are up 20.4% over twelve months including dividends.
- **From 52-week high: -11.2%** (66.0% above the low). Trading 11% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 0.64** (volatility 47%). Beta of 0.64 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BCRX · Page: https://foliofundamentals.com/stocks/bcrx

Not investment advice.